Nadzeya Haroshka/iStock via Getty Images Airline stocks surged early Wednesday after the U.S. and Iran agreed to a two-week ceasefire, easing concerns over disruptions in the Strait of Hormuz. Accordingly, the price of a barrel of Brent crude oil ( CO1:COM ) fell as much as 16% before settling around $94.3 a barrel. Fuel-sensitive sectors rallied in premarket trading, with American Airlines ( AAL ...
Nadzeya Haroshka/iStock via Getty Images Airline stocks surged early Wednesday after the U.S. and Iran agreed to a two-week ceasefire, easing concerns over disruptions in the Strait of Hormuz. Accordingly, the price of a barrel of Brent crude oil ( CO1:COM ) fell as much as 16% before settling around $94.3 a barrel. Fuel-sensitive sectors rallied in premarket trading, with American Airlines ( AAL ) up +6.2%, United Airlines ( UAL ) +8.7%, Southwest Airlines ( LUV ) +8.1%, Delta Air Lines ( DAL ) +6.8%, and JetBlue Airways ( JBLU ) +5.9%, helping lift the U.S. Global Jets ETF ( JETS ) up 7.7%. Separately, Delta ( DAL ) is also scheduled to report its first-quarter results later in the day. In Europe, Antofagasta ( ANFGF ), Lufthansa ( DLAKF ), Wizz Air ( WZZZY ) ( WZZAF ), Air France-KLM ( AFLYY ), and easyJet ( ESYJY ) were among the top gainers, each climbing more than 10% in morning trading. Airline stocks have been under pressure since mid ‑ February as escalating Middle East tensions pushed oil prices higher, raising concerns over fuel costs and squeezing profit margins. More on Delta Air Lines, American Airlines, etc. Delta Air Lines: Why It Is A Relative Winner (Rating Upgrade) Delta Air Lines Will Potentially Lead In This Year Of Chaos Delta Air Q1 Earnings Preview: A High Bar To Fly Over, Shares Fairly Valued DOT Sec. Duffy sees “room” for more airline M&A Transportation Sec. Duffy says there's room for U.S. airline consolidation
Maki Nakamura/DigitalVision via Getty Images Topline Summary and Update I've been on record as an optimist on the outlook for IDEAYA Biosciences ( IDYA ) starting around last year, due in large part to the untapped potential of their lead compound, darovasertib. As their story continues to evolve, IDYA is continuing to pick up new pipeline projects and push toward a critical readout in what is arg...
Maki Nakamura/DigitalVision via Getty Images Topline Summary and Update I've been on record as an optimist on the outlook for IDEAYA Biosciences ( IDYA ) starting around last year, due in large part to the untapped potential of their lead compound, darovasertib. As their story continues to evolve, IDYA is continuing to pick up new pipeline projects and push toward a critical readout in what is arguably their most important trial to date. Today, I want to digest recent updates on the progress of this trial and other pipeline progress and continue to make the case for optimism in this stock thesis. Pipeline Updates Darovasertib The main pipeline candidate for IDYA remains the protein kinase C inhibitor darovasertib, being explored as an option for patients with uveal melanoma harboring a specific, very common biomarker. As a reminder, uveal melanoma continues to represent an important unmet need, with no traditional chemotherapy, targeted therapy, or immunotherapy so far being able to really touch it. We have tebentafusp for patients of a certain HLA type, but uveal melanoma remains a mostly unmet need in cancer. There are two stories unfolding with darovasertib: as part of a combination in metastatic disease and as a single agent in the pre-surgical setting. For the former, we last saw an update on overall survival at the SMR meeting back in October 2025. Median overall survival for patients in this phase 1/2 study was 21.1 months, comparable to what has been seen with tebentafusp in selected patients and beating historical benchmarks that would be expected in this population. These findings are being further developed in the OptimUM-02 study, which IDYA anticipates will support a filing for approval with the FDA. Topline findings for patients with HLA*A2-negative disease have been guided for the last week of March 2026, but days before this timing, IDYA announced the readout would be delayed until after the database lock in the first half of April, with the data rea...
Dairy Boy founder Paige Lorenze may soon have some more cash to splash on renovations to the $4.7 million mansion she and fiancé Tommy Paul just purchased—after landing a buyer for her Connecticut starter home.
Dairy Boy founder Paige Lorenze may soon have some more cash to splash on renovations to the $4.7 million mansion she and fiancé Tommy Paul just purchased—after landing a buyer for her Connecticut starter home.
(RTTNews) - European stocks soared on Wednesday as a two-week Middle East ceasefire helped ease fears of supply disruptions in oil markets and tempered inflation concerns.
(RTTNews) - European stocks soared on Wednesday as a two-week Middle East ceasefire helped ease fears of supply disruptions in oil markets and tempered inflation concerns.